[ad_1]
Disease of genetic origin and still without cure causes an increase of mucus in the lung, leading to infections; there was no recourse available in Brazil
Anvisa approves the register of drugs to treat cystic fibrosis
Anvisa (National Health Surveillance Agency) approved the registration of a new cure for the treatment of cystic fibrosis
Cystic fibrosis is a disease of genetic origin and still incurable which causes accumulation of mucus in the lung, leading
According to the leaflet Orkambi (lumacaftor + ivacaftor), the use of the drug is not recommended in patients with rare diseases.
Another positive effect of the drug, according to Anvisa, is the improvement of nutritional assessments of those who undergo treatment.
Orkambi will be offered as a tablet in concentrations of 100 mg + 125 mg and 200 mg + 125 mg. The drug is indicated for patients over 6 years of age and adults for the treatment of cystic fibrosis
See also: Patients with cystic fibrosis face a lack of drugs in Pará
Source link
